Abstract 99P
Background
The KCSG AL20-17/KM23 trial assessed the efficacy of neratinib combined with trastuzumab in heavily pretreated patients with HER2-mutated solid tumors. This study aimed to investigate the potential of circulating tumor DNA (ctDNA) as a biomarker for predicting treatment outcomes with this dual anti-HER2 combination.
Methods
ctDNA samples were collected during the screening visit before treatment initiation and either at the end of treatment or upon disease progression. This report primarily focuses on analyzing the screening samples using Guardant360® to identify pathogenic mutations based on the ClinVar or OncoKB databases.
Results
Among the 40 enrolled patients, ctDNA from 32 individuals was successfully analyzed. Most patients exhibited HER2 mutations in their ctDNA consistent with those found in their tumor tissues. However, three patients showed no detectable HER2 mutations in their ctDNA, of whom two had stable disease, and one had progressive disease as their best response. Other prevalent mutations included TP53 mutations (n=20), EGFR amplification (n=6), PIK3CA amplification (n=3), HER2 amplification (n=3), and KRAS mutation (n=3). EGFR amplification tended to be associated with shorter survival, although not statistically significant (median PFS 2.02 vs 3.42 months, p = 0.055; median OS 5.98 vs 13.71 months, p = 0.153). The median ctDNA fraction was 5.705% (range: 0.11-71.97). Higher ctDNA fractions were associated with poorer survival outcomes, with a selected cutoff point of 11.47% (median PFS 4.87 vs 2.01 months, p = 0.02; median OS 13.71 vs 4.64 months, p = 0.036).
Conclusions
This study underscores the potential of ctDNA as a predictive and prognostic biomarker for patients with HER2-mutated advanced-stage solid tumors treated with neratinib and trastuzumab. The presence of HER2 mutations in ctDNA generally matched those in tumor tissues, and elevated ctDNA fractions were linked to poorer outcomes. Further research is necessary to validate the role of ctDNA in optimizing anti-HER2 therapy for HER2-mutated tumors.
Clinical trial identification
NCT06083662.
Editorial acknowledgement
Legal entity responsible for the study
Korean Cancer Study Group (KCSG).
Funding
Korean Cancer Study Group (KCSG); Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2206).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
Presenter: Li Lin
Session: Poster session 07
32P - Patient derived circulating tumor cell clusters for personalized chemotherapy
Presenter: Prashant Kumar
Session: Poster session 07
Resources:
Abstract
33P - Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors
Presenter: Noémie Luong
Session: Poster session 07
34P - A novel gene family underlying cancer cell resilience
Presenter: David Amici
Session: Poster session 07
35P - The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Presenter: Jianhui Ma
Session: Poster session 07
36P - Branched-chain amino acids metabolism reprogramming in trastuzumab primary resistant HER2 positive breast cancer
Presenter: Yijia Hua
Session: Poster session 07
37P - A consensus gene set facilitates enrichment analysis of cancer hallmarks
Presenter: Otília Menyhart
Session: Poster session 07
38P - Feasibility of expanding tumor-infiltrating lymphocytes from cryopreserved tumor specimens after long-term storage
Presenter: Daria Kuznetsova
Session: Poster session 07
39P - Search for rare copy number variants associated with hereditary breast cancer in Finnish case-control cohorts
Presenter: Timo Kumpula
Session: Poster session 07
40P - STOPIN: A new approach to solve the hematological toxicity of antibody-drug conjugates (ADC) with soft topoisomerase inhibitor
Presenter: Xinghai Wang
Session: Poster session 07